To include your compound in the COVID-19 Resource Center, submit it here.

Acceleron starts Phase II trial of ACE-083 to treat Charcot-Marie-Tooth disease

Acceleron Pharma Inc. (NASDAQ:XLRN) began a Phase II trial of ACE-083 to treat Charcot-Marie-Tooth disease. The trial’s

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE